Drug intelligence / Profile preview

AZP-IL4R-AD1

Development stage: Unknown
Lead developer: Azcuris
Modality: Small Molecules
Administration: Oral

Overview

AZP-IL4R-AD1 is a first-in-class, orally available small molecule interleukin-4 receptor (IL-4R) inhibitor being developed by Azcuris for the treatment of atopic dermatitis. It works by antagonizing the IL-4 receptor alpha (IL-4Rα), which is involved in the type-2 inflammatory pathway that plays a key role in atopic diseases. By blocking this receptor, AZP-IL4R-AD1 aims to inhibit the signaling pathways of IL-4 and IL-13, key cytokines that drive type 2 inflammatory responses associated with atopic dermatitis.

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on AZP-IL4R-AD1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZP-IL4R-AD1.

Explore the full profile